Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

Colorectal Cancer Clinical Trial

Official title: Evaluation of Liver MR With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic Metastases

Status Recruiting

Clinical Trial Summary

If an abbreviated HBP protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.

Clinical Trial Description

The goal is to:

• Estimate and compare the diagnostic performance, including sensitivity, specificity, positive/negative predictive value, and area under the receiver operating characteristics (AUROC), of abbreviated protocol liver magnetic resonance (MR) with hepatobiliary phase (HBP) using gadobenate dimeglumine for detecting liver metastases, with 1) abbreviated protocol liver MR with HBP using gadoxetate disodium, 2) standard of care complete protocol liver MR using gadoxetate disodium, and 3) complete protocol liver MR using gadobenate dimeglumine.

• Estimate and compare quantitative measures of HBP images (liver enhancement ratio, lesion contrast to noise and signal to noise ratios [CNR and SNR]) for both gadobenate dimeglumine and gadoxetate disodium.

• Qualitatively assess the preference, or lack thereof, of radiologists regarding the images generated by abbreviated protocol liver MR with HBP using gadobenate dimeglumine versus abbreviated protocol liver MR with HBP using gadoxetate disodium. ;

Related Conditions & MeSH terms

• Colorectal Cancer
• Liver Metastases
• Neoplasm Metastasis
• Oligometastatic Disease

• NCT number: NCT04973007
• Study type: Interventional
• Source: University of Colorado, Denver
• Contact: Samuel Chang, MD
• Phone: 720-848-0000
• Email: SAMUEL.CHANG@CUANSCHUTZ.EDU
• Status: Recruiting
• Phase: Phase 4
• Start date: June 22, 2021
• Completion date: December 9, 2024